牛磺酸调节缺氧性肺、脑血管反应的机理研究

本实验从磷脂酶Ａ＿２（ＰＬＡ＿２）、前列腺素（ＰＧｓ）、白三烯（ＬＴｓ）和过氧化脂质（ＬＰＯ）方面探讨了牛磺酸调节肺、脑血管对急、慢性缺氧反应的机制。急性缺氧时狗出肺与出脑血中ＬＰＯ增加,ＰＬＡ,活性有升高趋势,但出脑与出肺（入脑）血相比无显著性差异。出肺与出脑血中ＬＴＣ＿４、ＴＸＢ＿２、６－Ｋｅｔｏ－ＰＧＦ＿（１ａ）及ＴＸＢ＿２／６－Ｋｅｔｏ－ＰＧＦ＿（１ａ）比值均升高。慢性缺氧大鼠肺、脑组织中ＰＬＡ＿２活性均升高。牛磺酸增加缺氧时６－Ｋｅｔｏ－ＰＧＦ＿（１ａ）,减弱其它变化。提示牛磺酸对缺氧性肺缩血管反应的调节作用可能与降低缺氧时ＰＬＡ＿２活性,抑制脂质过氧化和ＬＴＣ＿４、ＴＸＡ＿２生成,降低ＴＸＡ＿２／ＰＧＩ＿２比值有关;而牛磺酸减弱缺氧性脑舒血管反应不是直接通过上述变化起作用的。     

磷脂酶A2对中性粒细胞趋化和粘附的影响

胰源性１４×１０￣３ｕ磷脂酶Ａ＿２（ＰＬＡ＿２）在体外同大鼠中性粒细胞（ＰＭＮ）培养６０ｍｉｎ后,细胞对ＴＮＦ趋化增强,培养１０ｍｉｎ后上清液中血栓素（ＴＸＢ＿２）含量比正常增高（Ｐ＜０．０１）。前列环素（ＰＧＩ＿２）含量不变。ＰＬＡ＿２激动剂Ａ２３１８７也能显著加强中性粒细胞对ＴＮＦ的趋化,并伴有ＴＸＢ＿２释放增多（Ｐ＜０．０１）。此外,ＰＬＡ＿２和Ａ２３１８７还显著增强ＰＭＮ对玻璃珠的粘附活性。使用ＰＬＡ＿２抑制剂二溴苯乙酮（ＰＢＰＢ）和ＰＬＡ＿２多克隆抗体可抑制外源性ＰＬＡ＿２对ＰＭＮ趋化和粘附的增强作用,但对Ａ２３１８７的调节作用无效。以上结果表明ＰＬＡ＿２激活及其代谢产物可能介导ＰＭＮ趋化和粘附作用。     

磷脂酶A2介导肿瘤坏死因子诱发的中性粒细胞趋化和粘附增强

肿瘤坏死因子（ＴＮＦ）对外周中性粒细胞（ＰＭＮ）具有重要调节作用。本文采用生化及放射免疫技术,观察体外重组ＴＮＦ对ＰＭＮ趋化、粘附及血栓素Ｂ２（ＴＸＢ２）和前列环素（６－ｋｅｔｏ－ＰＧＦ１ａ）释放的改变。ＴＮＦ（１００ｍｇ／ｍｌ）处理６０ｍｉｎ后,ＰＭＭ对白细胞趋化因子（ＦＭＬＰ）趋化和玻璃珠粘附性均显著增加,同时伴有ＴＸＢ２释放增多,６－Ｋｅｔｏ－ＰＧＦ１ａ不变。这提示ＴＮＦ体外促ＰＭＭ趋化和粘     

PAF对肺内小动脉平滑肌细胞TXA_2，PGI_2乃Ca~（2＋）－ATPase的影响

本工作采用分离培养家兔肺内小动脉平滑肌细胞（ＰＡＳＭＣｓ），观察了外源性血小板活化因子（ｐｌａｔｅｌｅｔａｃｔｉｖａｔｉｎｇｆａｃｔｏｒ，ＰＡＦ）、ＢＮ５２０２１（ＰＡＦ受体拮抗剂）、吲哚美辛、维拉帕米对ＰＡＳＭＣｓ产生血栓素Ａ_２（ＴｘＡ_２）、前列环素（ＰＧＩ_２）及对细胞膜Ｃａ~（２＋）－ＡＴＰａｓｅ活力的影响。结果表明：（１）基础状态下ＰＡＳＭＣｓ存在花生四烯酸（ＡＡ）代谢。（２）外源性ＰＡＦ通过受体后途径激活环加氧酶促进ＡＡ代谢致ＴＸＡ_２及ＰＧＩ－２增加，ＴＸＡ_２／ＰＧＩ_２比值无明显变化。（３）外源性ＰＡＦ能直接抑制Ｃａ~（２＋）－ＡＴＰａｓｅ活力。（４）维拉帕米可逆转ＰＡＦ抑制ＰＡＳＭＣｓ膜Ｃａ~（２＋）－ＡＴＰａｓｅ活力的效应。     

DDPH对猪肺动脉平滑肌细胞PDGF·BB和bFGF表达的影响：免疫细胞化学研究

ＤＤＰＨ［１－（２．６－二甲基苯乙氧基）－２－（３．４二甲氧基苯乙胺基）丙烷盐酸盐］是南京药科大学合成的降压新化合物,也具有降低肺动脉高压和抑制肺动脉平滑肌细胞增殖作用。本实验用细胞培养、免疫细胞化学、图像分析、３Ｈ－ＴｄＲ、细胞周期测定等方法,进一步探讨ＤＤＰＨ对缺氧性肺动脉平滑肌细胞（ＰＡＳＭＣＳ）增殖的抑制机制。结果：缺氧促进肺动脉内皮细胞（ＰＡＥＣｓ）的ＰＤＧＦ·ＢＢ和ｂＦＧＦ两种生长因子的表达（积分光密度ＯＤ值）增高。缺氧内皮细胞条件培养液（ＨＥＣＣＭ）能促进ＰＡＳＭＣＳ的ＰＤＧＦ·ＢＢ的ＯＤ值增高,ｂＦＧＦ的ＯＤ值无明显改变。加药组（ＨＥＣ－ＣＭ＋ＤＤＰＨ）的ＰＤＧＦ·ＢＢ和ｂＦＧＦ的ＯＤ值均显著降低,尤以ＰＤＧＦ·ＢＢ的ＯＤ值减少最多．提示：ＤＤＰＨ能抑制ＨＥＣＣＭ引起ＰＡＳＭＣＳ的ＰＤＧＦ·ＢＢ和ｂＦＧＦ表达增多和细胞增殖。结果与大鼠实验观察相符。     

畲族Gc、PGM1、AcP_1、6-ΡGD、ADA和AK1的遗传多态性

对畲族血浆组特异性成分（Ｇｃ）、红细胞磷酸葡萄糖变位酶１（ＰＧＭ１）、酸性磷酸酶（ＡｃＰ１）、６－磷酸葡萄糖酸脱氢酶（６－ＰＧＤ）、腺苷脱氨酶（ＡＤＡ）、腺苷酸激酶（ＡＫ１）的遗传多态性进行了研究。Ｇｃ与ＰＧＭ１是用薄层聚丙烯酰胺凝胶等电聚焦分析的,ＡｃＰ１、６－ＰＧＤ、ＡＤＡ及ＡＫ１是用淀粉凝胶电泳分析的。各基因座的基因频率分别为Ｇｃ＊１Ｆ０．４７２２、Ｇｃ＊１Ｓ０．２４２１、Ｇｃ＊２０．２７３８;ＰＧＭ１＊１Ａ０．５３５７、ＰＧＭ１＊１Ｂ０．１６２７、ＰＧＭ１＊２Ａ０．１５８７、ＰＧＭ１＊２Ｂ０．１４２９;ＡｃＰ＊１Ａ０．１８２５、ＡｃＰ１＊Ｂ０．８１７５;６－ＰＧＤ＊Ａ０．９６８３、６－ＰＧＤ＊Ｂ０．０２７８;ＡＤＡ＊１０．９８８１、ＡＤＡ＊２０．０１１９;ＡＫ１＊１１．００００。畲族Ｇｃ、ＰＧＭ１、ＡｃＰ１、６－ＰＧＤ和ＡＤＡ基因为多态,而ＡＫ１基因为单态。发现１例带有６－ＰＧＤ＊Ｒ和３例带有Ｇｃ＊１Ａ２变异等位基因的个体,其中Ｇｃ＊１Ａ２基因频率为０．０１１９,达到多态水平。     

大熊猫基因指纹探针F2ZGP96060801的研制及比较实验分析

利用ＡＢＩ－３９４型ＤＮＡ合成仪合成的寡核苷酸５－「Ａ（Ｘ）ｎ－ｘＴＣＣＡＣ」ｎ－３,经高效液相色谱仪纯化后,制备成了命名为为Ｆ２ＺＧＰ９６０６０８０１的大熊猫基因指纹探针,用同位素标记法标记Ｆ２ＺＧＰ９６０６０８０１,ＬＺＦ－Ｉ、朋５、３３．６和（ＣＡＣ）６／ＧＴＧ）５等５种基因指纹探针,比较检测了大熊猫随机个体的被毛、大熊猫３雄配Ｉ雌所产１个双胞胎计６只个体的福尔马林固定的肝组织和粪便中的胃肠     

缺氧性肺动脉高压大鼠肺组织中血小板源性生长因子和c－myc基因表达增强

本研究分析了大鼠肺组织中血小板源性生长因子Ａ链、Ｂ链（ＰＤＧＦ－Ａ,ＰＤＧＦ－Ｂ）和ｃ－ｍｙｃ原癌基因ｍＲＮＡ在正常和缺氧时的含量变化。正常肺组织可表达１．７ｋｂ的ＰＤＧＦ－ＡｍＲＮＡ和３．５ｋｂ的ＰＤＧＦ－ＢｍＲＮＡ,还有少量２．２ｋｂｃ－ｍｙｃｍＲＮＡ。在缺氧过程中,ＰＤＧＦ－Ｂ链ｍＲＮＡ和ｃ－ｍｙｃｍＲＮＡ迅速增加,至缺氧１４ｄ时,分别为正常的３倍和５倍。而ＰＤＧＦ－ＡｍＲＮＡ在缺氧７ｄ时增高,而后又略有降低。结果表明：缺氧的肺组织局部生成的ＰＤＧＦ激活了ｃ－ｍｙｃ原癌基因,这对于缺氧性肺动脉高压的形成具有重要作用。     

神经节苷脂GM_3对人白血病J6－2细胞磷脂酰胆碱代谢的影响

神经节苷脂ＧＭ３诱导人单核样白血病Ｊ６－２细胞沿单核／巨噬细胞途径分化．在ＧＭ３诱导分化同时,Ｊ６－２细胞磷脂代谢发生了显著变化．采用（（３２）Ｐ）Ｐｉ、［ＧＨ３－３Ｈ］胆碱和［ＣＨ３－３Ｈ］ＳＡＭ参入实验对ＧＭ３影响Ｊ６－２细胞ＰＣ代谢的机制进行了初步的探讨．ＧＭ３促进［（３２）Ｐ］Ｐｉ参入Ｊ６－２细胞ＰＣ;抑制［ＣＨ３－３Ｈ］胆碱参入ＰＣ及ＰＣ合成的前体磷酸胆碱及ＣＤＰ－胆碱;ＧＭ３促进［ＣＨ３－３Ｈ］ＳＡＭ参入ＰＣ,但抑制［ＣＨ３－３Ｈ］ＳＡＭ参入ＰＣ合成的前体胆碱、磷酸胆碱和ＣＤＰ－胆碱．上述结果提示,ＧＭ３抑制Ｊ６－２细胞ＰＣ合成的ＣＤＰ－胆碱途径,促进ＰＣ合成的ＰＥ甲基化途径．     

前列腺素F2α对大鼠肾小球系膜细胞DNA合成的影响

本实验应用（＾３Ｈ）胸腺嘧啶核苷（＾３Ｈ－ＴｄＲ）掺入法测定前列腺素Ｆ２α（ＰＧＦ２α）对大鼠肾小球系膜细胞ＤＮＡ合成的作用,测定系膜细胞合成的二脂酰甘油（ＤＡＧ）及磷酸肌醇（ＩＰ）。结果表明,ＰＧＦ２α促进系膜细胞的ＤＮＡ合成、ＤＡＧ及ＩＰ的生成。提示ＰＧＦ２α使系膜细胞的磷脂酶Ｃ活化,产生ＩＰ及ＤＡＧ,激活蛋白激酶Ｃ,从而促进ＤＮＡ合成及细胞增殖。     

Cardiovascular and sympathetic nerve responses induced by intracerebroventricular injections of prostacyclin in rats

Intracerebroventricular (ICV) injections of prostacyclin (PGI2) produced biphasic blood pressure responses consisting of an initial hypotensive phase followed by a sustained pressor phase in awake rats. Heart rate increased following such injections in either awake or anesthetized rats. PGI2, 1 microgram, produced biphasic responses and, 10 micrograms, purely vasodepressor responses in anesthetized rats, but abdominal sympathetic nerve firing recorded was consistently increased. Hypophysectomy did not affect the hypotensive phase of the responses. These results indicate that the initial hypotension can not be explained by centrally-induced changes in sympathetic nerve activity or vasopressin release, but may be due to peripheral effects of PGI2 leaking from the injection site.     

Influence of verapamil on central and peripheral effects of prostacyclin on circulatory system in rats

The influence of verapamil on cardiovascular effects of prostacyclin (PGI2) in rats was examined. PGI2 administered into the lateral brain ventricle (i.c.v.) or intravenously (i.v.) in a dose of 2.7 x 10(-8)mol evoked hypotension and tachycardia. Pretreatment with verapamil in a dose of 2.0 x 10(-5)mol/kg given intraperitoneally (i.p.) diminished hypotensive effect of PGI2 i.c.v. as well as inhibiting the influence of PGI2 i.c.v. and i.v. upon the heart rate. Bolus injection of PGI2 in a dose of 2.7 x 10(-10), 2.7 x 10(-9) or 2.7 x 10(-8)mol evoked biphasic inotropic and chronotropic effects on isolated rat heart. Short-term increase of the contractile force together with bradycardia and afterwards long-lasting decrease of contractility with sustained, slight tachycardia were observed. Verapamil in a concentration of 1.0 x 10(-6)M blocked biphasic inotropic effect and bradycardia after PGI2 administration. Because some central and peripheral cardiovascular effects of PGI2 were inhibited by verapamil, it is concluded that PGI2 may participate in transmembrane calcium ions movements.     

Hypotensive response to prostacyclin and 6-keto-PGE1 following hepatectomy in the rat

Prostacyclin (PGI2) is metabolized to 6-keto-prostaglandin E1 (6-keto-PGE1) which is more stable yet equipotent to PGI2 in lowering systemic arterial blood pressure in the dog. In this study, partial hepatectomy was performed to determine the role of the liver in the vasodepressor response to both intravenously administered PGI2 and 6-keto-PGE1. The magnitude and the duration of systemic hypotensive responses were measured in hepatectomized and sham-operated male Wistar rats following less than maximal, equidepressor doses of PGI2 (0.3 microgram/kg), 6-keto-PGE1 (1.0 microgram/kg), and also PGE1 (3.0 micrograms/kg) and PGE2 (3.0 micrograms/kg). Hepatectomy did not significantly alter the magnitude of the systemic hypotensive response to any of the prostaglandins tested. This indicates that the liver and hepatic circulation do not contribute significantly to the hypotensive effect of these prostaglandins by alterations of systemic vascular resistance, venous pooling of blood, or the generation of additional vasoactive metabolites as may be expected following administration of these prostaglandins. However, hepatectomy did significantly increase the duration of the hypotensive response to PGI2 and 6-keto-PGE1 but not PGE1 or PGE2. We conclude that in vivo, the liver has a more significant role in PGI2 and 6-keto-PGE1 inactivation than in the inactivation of PGE1 and PGE2 when administered intravenously. These results also support the relatively greater significance of the lung in the inactivation of PGE1 and PGE2 in vivo.     

Mechanism of cyclosporin A-induced inhibition of prostacyclin synthesis by macrophages

In vitro studies of PG production over a 24 h period by adherent rat peritoneal macrophages activated by serum-opsonized zymosan revealed that CSA (0.3-10 micrograms/ml) caused a dose-related inhibition of PGI2 (assayed as 6-oxo-PGF1 alpha) formation. Indomethacin (IND, 0.01-10 micrograms/ml) and dexamethasone (DEX, 0.01-10 micrograms/ml) also inhibited the PG production in a dose-related manner. When arachidonic acid (10 micrograms/ml) was added together with the inhibitors, there was no change in the level of PGI2 produced by IND-treated cells whilst the PGI2 levels of DEX- and CSA-treated cells were elevated to the control level. Therefore CSA like DEX does not inhibit cyclo-oxygenase activity. However unlike DEX, CSA (1-30 micrograms/ml) caused inhibition of phospholipase A2 (PLA2) activity when assayed on the hydrolysis of a synthetic substrate by pancreatic PLA2 in a cell-free system. The direct inhibition of PLA2 might well be a manifestation of the fundamental activity of CSA on immunocompetent cells.     

sPLA(2) cooperates with cPLA(2)alpha to regulate prostacyclin synthesis in human endothelial cells

The first step in prostacyclin (PGI(2)) synthesis involves the generation of arachidonic acid (AA) from membrane phospholipids mediated by the 85 kDa cytosolic phospholipase A(2) (cPLA(2)alpha). The current study examined the effects of secretory PLA(2)s (sPLA(2)s) on PGI(2) production by human umbilical vein endothelial cells (HUVEC). We demonstrate that exposure of HUVEC to sPLA(2) dose- and time-dependently enhances AA release and PGI(2) generation. sPLA(2)-stimulated AA mobilisation was blocked by AACOCF(3), an inhibitor of cPLA(2)alpha, suggesting cross-talk between the two classes of PLA(2). sPLA(2) induced the phosphorylation of cPLA(2)alpha and enhanced the phosphorylation states of p42/44(mapk), p38(mapk), and JNK, concomitant with elevated AA and PGI(2) release. The MEK inhibitor PD98059 attenuated sPLA(2)-stimulated cPLA(2)alpha phosphorylation and PGI(2) release. These data show that sPLA(2) cooperates with cPLA(2)alpha in a MAPK-dependent manner to regulate PGI(2) generation and suggests that cross-talk between sPLA(2) and cPLA(2)alpha is a physiologically important mechanism for enhancing prostanoid production in endothelial cells.     

Split-dose sparing of gamma-ray-induced pulmonary endothelial dysfunction in rats

The purpose of this study was to determine whether radiation-induced pulmonary endothelial dysfunction exhibits split-dose sparing. Rats were sacrificed 2 months after a range of 60Co gamma-ray doses (0-40 Gy) delivered to the right hemithorax in either a single fraction or in two equal fractions separated by 24 h. Pulmonary angiotensin converting enzyme (ACE) activity, plasminogen activator (PLA) activity, and prostacyclin (PGI2) and thromboxane (TXA2) production served as indices of lung endothelial function. There were dose-dependent decreases in ACE and PLA activity and increases in PGI2 and TXA2 production after both single and split-dose exposures. The D2-D1 values determined from the two-fraction minus single-fraction isoeffective doses were 3.9 Gy for ACE activity, 7.2 Gy for PLA activity, 4.8 Gy for PGI2 production, and 4.7 Gy for TXA2 production. Thus these data demonstrate that over the present range of radiation doses approximately 4-7 Gy is repairable as subeffective endothelial damage during the 24-h interval between fractions. These values agree with previously published estimates of split-dose sparing in mouse lung based on lethality and breathing rate assays.     

Prostaglandin production in human coronary artery endothelial cells is modulated differentially by selective phospholipase A(2) inhibitors

Atherosclerotic plaque formation is a dynamic process involving repeated injury and inflammation of the endothelium. We have demonstrated previously that thrombin and tryptase stimulation of human coronary artery endothelial cells (HCAEC) leads to increased phospholipase A(2) (PLA(2)) activity and generation of membrane phospholipid derived inflammatory metabolites, including eicosanoids and platelet activating factor. Thus, our hypothesis is that selective PLA(2) inhibitors have therapeutic potential as anti-inflammatory agents. Stimulation of confluent HCAEC monolayers with thrombin or tryptase resulted in a concentration and time-dependent increase in both prostaglandin E(2) (PGE(2)) and prostacyclin (PGI(2)) production. Pretreatment with PX-18 to inhibit secretory PLA(2) or BEL to inhibit calcium-independent PLA(2) prior to thrombin or tryptase stimulation resulted in a significant inhibition of both PGI(2) and PGE(2) release. However, pretreatment with methyl arachidonyl fluorophosphonate (MAFP), a widely used inhibitor of cytosolic PLA(2) isoforms, resulted in a significant potentiation of both thrombin and tryptase stimulated PGI(2) and PGE(2) release as a consequence of increased free arachidonic acid production. We conclude that the use of selective PLA(2) inhibitors may be of therapeutic benefit in the development and progression of atherosclerosis, however, the development of such an agent requires rigorous screening.     

Angiotensin II-induced ET and PGI2 release in rat aortic endothelial cells is mediated by PKC.

Angiotensin II (Ang II) has been shown to stimulate the release of immunoreactive endothelin (ET) from cultured bovine ECs. Also, Ang II activates phospholipase A2 (PLA2) in various tissues, resulting in the release of arachidonic acid and formation of prostaglandins. We used rat aortic endothelial cells to investigate the role of protein kinase C (PKC) in Ang II-induced release of both ET and prostacyclin (PGI2). The amount of ET and PGI2 produced were determined by radioimmunoassay. Ang II-induced the release of both ET and PGI2. Pretreatment with 10(-6) M of any one of the PKC inhibitors: 1-(5-isoquinolinesulfonyl) piperazine(CL), staurosporine, 1-(5-isoquinolinesulfonylmethyl)piperazine(H7), and calphostin C blocked AII-induced release of both ET and PGI2. In rat aortic endothelial cells that were treated with either AII or PDBu, PKC enzyme assay showed PKC was translocated from the cytosol to the membrane which indicates activation. This suggests that PKC mediates AII-induced ET and PGI2 release. In summary, AII activates PKC which inhibits rat aortic endothelial cells ET and PGI2 formation, and this inhibition can be overcome by pretreatment with PKC inhibitors.     

Trans fatty acids in partially hydrogenated soybean oil inhibit prostacyclin release by endothelial cells in presence of high level of linoleic acid

Partially hydrogenated soybean oil (PHSBO) and natural soybean oil (SBO) were obtained from a commercial source and their fatty acids were fractionated into saturates, monoenes and diene fractions. The present study compared the effect of the total, monoene and diene fatty acid fractions of PHSBO with those of the SBO on the fatty acid composition of the cell phospholipids (PL) and the prostacyclin (PGI(2)) release by endothelial cells (EC) in culture. Results showed that arachidonic acid (AA) level decreased significantly and linoleic acid (LA) significantly increased in the cells incubated with the diene fraction or the monoene fraction of PHSBO plus 18:2 at 3:1 ratio compared to the cell incubated with those fractions of SBO. These changes were attributed to the inhibition of LA conversion to AA by trans 18:1 and 18:2 isomers present in the monoene or diene fractions of PHSBO leading to a significant decrease of PGI(2) released by the cells incubated with monoene or diene fractions of PHSBO. The cells incubated with the monoene of PHSBO or SBO plus 18:2 at a 1:1 ratio showed no inhibition of LA conversion to AA and the level of AA was almost equal in their PL, but the PGI(2) released by the cells incubated with the monoene of PHSBO was significantly less than the cells incubated with the monoene of SBO. This decrease was not related to the inhibition of PGI(2) synthesizing enzymes or phospholipase (PLA(2)) activities. Our data show that trans acids in PHSBO inhibited the PGI(2) release by the cells through controlling the level of AA as substrate, either by (a) inhibiting the conversion of LA to AA or (b) by shunting the free AA released by the PLA(2) action to metabolism by another pathway leaving less AA available for PGI(2) synthesis.     

Stability of authentic PGI2 during routine extraction. Clarification of the nature and sequence of products formed by the rat stomach including the origin of the ozonolysis products reported in 1971.

Authentic PGI2 and PGI2 formed by rat stomach homogenates were carried through a simple extraction and purification procedure to explore the feasibility of isolation of this biologically active bicyclic ether product of arachidonic acid. The integrity of PGI2 was followed throughout by bioassay on the rat blood pressure. In this system we recently reported that PGI2 has very potent hypotensive actions which are easily distinguishable from those observed for PGE2 (14). Our results indicate that PGI2 survives the initial extraction steps (i.e. ethanol extraction, diethyl ether - HCl extraction and methylation) up to the step involving thin layer chromatography with an acidic developing solvent system. This latter procedure converts PGI2 entirely into a stable derivative, 6-keto-PGF1alpha (3,8--10). Oxidative ozonolysis of the methyl ester acetate derivative of authentic 6-keto PGF1alpha reveals products identical to those reported by Pace-Asciak and Wolfe in 1971 (1) which are also produced from authentic PGI2. This data sheds new light into 1) the nature of the biological product formed by stomach homogenates, 2) its transformation into 6-keto PGF1alpha during purification and 3) the origin of the ozonolysis products in the experiments reported in 1971.